...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Anti‐angiogenesis effect of β‐D‐mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model
【24h】

Anti‐angiogenesis effect of β‐D‐mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model

机译:β-D-甘露糖醛酸(M2000)作为实验模型中具有免疫抑制性能的新型NSAID的抗血管生成效应

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Angiogenesis is a process through which new capillaries are formed from pre‐existing ones, which contributes significantly to the pathogenesis of numerous diseases, such as cancer and chronic inflammatory disorders. The β‐D‐mannuronic acid (M2000) is a novel non‐steroidal anti‐inflammatory drug (NSAID) with immunosuppressive effects and is a matrix metalloproteinase (MMP) inhibitor. This research aimed to study the anti‐angiogenesis effects of M2000 under in vitro and in vivo models. The cytotoxic and anti‐proliferative effects of M2000 were examined using the trypan blue method and the MTT assay, respectively. The 3D collagen‐cytodex model and the chick?chorioallantoic membrane?(CAM) assay were then used to evaluate the anti‐angiogenesis property of M2000. Cytotoxicity assay revealed that M2000 (at concentrations of less than 100?μg/mL) had no cytotoxic effect on human umbilical vein endothelial cells?(HUVECs). It was also illustrated that M2000 had little or no anti‐proliferative effect on HUVECs. In addition, the anti‐angiogenesis effects of M2000 were shown to be marginal in the in vitro model and both significant and dose‐dependent in the in vivo status. This study showed that M2000 could be considered as an anti‐angiogenic molecule which more likely exerts its activity mainly via indirect effects on endothelial cells and its anti‐inflammatory effects may partly be attributable to its anti‐angiogenic activity. Therefore, it could be recommended as a candidate for prevention and treatment of cancer, chronic inflammatory diseases, and other angiogenesis‐related disorders.
机译:总结血管生成是一种过程,通过预先存在新的毛细血管,这对癌症和慢性炎症性疾病进行了大量疾病的发病机制。 β-D-甘露糖醛酸(M2000)是一种具有免疫抑制作用的新型非甾体抗炎药(NSAID),是基质金属蛋白酶(MMP)抑制剂。该研究旨在在体外和体内模型中研究M2000的抗血管生成效应。使用Trypan蓝方法和MTT测定分别检查M2000的细胞毒性和抗增殖效果。然后,使用3D胶原蛋白-Cytodex模型和小鸡?培训膜膜?(凸轮)测定法评估M2000的抗血管生成性能。细胞毒性测定显示,M2000(浓度小于100≤μg/ ml)对人脐静脉内皮细胞没有细胞毒性作用?(HUVECS)。还表明M2000对Huvecs对Huvecs几乎没有抗增殖作用。此外,M2000的抗血管生成效应显示在体外模型中是边缘的,并且显着和剂量依赖于体内状态。该研究表明,M2000可以被认为是一种抗血管生成分子,其越来越可能主要通过对内皮细胞的间接影响而施加的活性,其抗炎作用可能部分是其抗血管生成活性。因此,可以推荐作为预防和治疗癌症,慢性炎症性疾病和其他相关疾病的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号